Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.61 |
| ▸ | CCR1 | P32246 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | MAT2A | P31153 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3150989 | 0.93 | ELANE (0.62) | ELANECCR1MEN1KMT2ANPSR1 | |
| SCHEMBL2273635 | 0.86 | ELANE (0.81) | ELANECCR1MEN1KMT2AMAPT | |
| SCHEMBL27749321 | 0.83 | ELANE (0.66) | ELANECCR1MEN1KMT2AMAPT | |
| SCHEMBL597391 | 0.79 | ELANE (0.58) | ELANECCR1MEN1KMT2AMAPT | |
| SCHEMBL2277940 | 0.78 | ELANE (0.82) | ELANECCR1MEN1KMT2AMAPT | |
| SCHEMBL3147872 | 0.78 | ELANE (0.60) | ELANE | |
| SCHEMBL27848638 | 0.77 | ELANE (0.49) | ELANECCR1MEN1KMT2AMAPT | |
| SCHEMBL3656275 | 0.77 | ELANE (0.51) | ELANECCR1MEN1KMT2AMAPT | |
| SCHEMBL2273394 | 0.76 | ELANE (1.00) | ELANECCR1MEN1KMT2A | |
| SCHEMBL4452188 | 0.76 | KMT2A (0.51) | ELANECCR1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2018375-B1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL. | ASTRAZENECA AB (SE) | 2010-03-03 | — | — | EP | claimed |